Get the Stockscreener App
298.40
0.26%
-0.77
Madrigal Pharmaceuticals Inc stock is traded at $298.40, with a volume of 300.05K.
It is down -0.26% in the last 24 hours and up +7.48% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$299.17
Open:
$298.92
24h Volume:
300.05K
Relative Volume:
0.89
Market Cap:
$6.63B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-11.88
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-10.69%
1M Performance:
+7.48%
6M Performance:
-9.06%
1Y Performance:
+5.27%
1-Day Range:
$296.17
$301.82
1-Week Range:
$296.17
$337.40
52-Week Range:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
298.40 | 6.64B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockDiscover breakthrough stocks before the crowd - jammulinksnews.com
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire
Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - Autocar Professional
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financia - GuruFocus
Madrigal Pharmaceuticals, Inc. Announces Second-Quarter 2025 Financial Results Release and Webcast Details - Quiver Quantitative
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire Inc.
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating - TipRanks
Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl - MSN
Madrigal Pharmaceuticals: Strategic Financing and Growth Potential Justify Buy Rating - TipRanks
What drives Madrigal Pharmaceuticals Inc. stock priceHigh-velocity gains - Autocar Professional
Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com
Madrigal Pharmaceuticals Secures $500 Million in Senior - GlobeNewswire
Madrigal's $500M Financing: Cementing Leadership in the High-Growth MASH Market - AInvest
Madrigal Pharmaceuticals Secures $500M Credit Facility - TipRanks
Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility - GuruFocus
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured - GuruFocus
Madrigal secures $500 million credit facility to advance MASH pipeline - Investing.com Australia
Madrigal Pharmaceuticals Secures $500 Million Senior Secured Credit Facility to Enhance MASH Pipeline and Support Strategic Expansion - Quiver Quantitative
Madrigal secures $500 million credit facility to advance MASH pipeline By Investing.com - Investing.com UK
Citizens JMP reiterates Madrigal stock rating on strong Rezdiffra uptake By Investing.com - Investing.com Canada
10 Most Undervalued Healthcare Stocks to Buy According to Analysts - Insider Monkey
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MSN
Madrigal gains after Rezdiffra patent win - MSN
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - MSN
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Taub Rebecca | Director |
Jul 18 '25 |
Sale |
350.00 |
1,000 |
350,005 |
461,044 |
| FRIEDMAN PAUL A | Director |
Jul 18 '25 |
Option Exercise |
9.45 |
1,400 |
13,230 |
188,564 |
| FRIEDMAN PAUL A | Director |
Jul 18 '25 |
Sale |
350.03 |
1,400 |
490,044 |
187,164 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):